Literature DB >> 28610818

Effect of pre-emptive analgesia on clinical parameters and tissue levels of TNF-α and IL-1β in third molar surgery: a triple-blind, randomized, placebo-controlled study.

A F M Albuquerque1, C S R Fonteles2, D R do Val3, H V Chaves4, M M Bezerra4, K M A Pereira2, P G de Barros Silva5, B B de Lima6, E C S Soares2, T R Ribeiro2, F W G Costa7.   

Abstract

This study aimed to evaluate whether pre-emptive analgesia modifies the tissue expression of tumour necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-1β), and whether there is an association with postoperative surgical outcomes. A triple-blind, randomized, placebo-controlled study of patients undergoing mandibular third molar removal was performed. Volunteers were allocated randomly to receive etoricoxib 120 mg, ibuprofen 400 mg, or placebo 1h before surgery. Twenty-four surgical sites per group were required (95% confidence level and 80% statistical power). Pain scores differed significantly between groups (P<0.001). Etoricoxib and ibuprofen reduced pain scores compared to placebo (P<0.05). Pain scores peaked at 4h postoperative in the experimental groups, but at 2h postoperative in the placebo group (P<0.05). A significant reduction in TNF-α concentration from time 0' to time 30' was seen for ibuprofen (P=0.001) and etoricoxib (P=0.016). The ibuprofen group showed a significant reduction in IL-1β levels from time 0' to time 30' (P=0.038). In conclusion, TNF-α and IL-1β levels and the inflammatory events in third molar surgery were inversely associated with the degree of cyclooxygenase 2 selectivity of the non-steroidal anti-inflammatory drugs used pre-emptively. Patients given pre-emptive analgesia showed significant reductions in the clinical parameters pain, trismus, and oedema when compared to the placebo group.
Copyright © 2017 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IL-1β; TNF-α; inflammatory events; non-steroidal anti-inflammatory drugs; third molar

Mesh:

Substances:

Year:  2017        PMID: 28610818     DOI: 10.1016/j.ijom.2017.05.007

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  9 in total

1.  Efficacy and safety of selective COX-2 inhibitors for pain management after third molar removal: a meta-analysis of randomized clinical trials.

Authors:  Albert González-Barnadas; Octavi Camps-Font; Pablo Martín-Fatás; Rui Figueiredo; Cosme Gay-Escoda; Eduard Valmaseda-Castellón
Journal:  Clin Oral Investig       Date:  2019-04-23       Impact factor: 3.573

2.  The impact of partially removing the Bichat fat pad in the linear facial measurements, satisfaction with facial aesthetics and quality of life: a single-arm CONSORT-guided clinical trial.

Authors:  Kamila França Pimentel; Maria Gabriela de Lima Sousa; Andressa Dos Santos Passos; Ravy Jucá Farias; Janaina Motta Guerra; Fabio Wildson Gurgel Costa; Fabrício Bitu Sousa; Paulo Goberlânio Barros Silva; Edson Luiz Cetira Filho
Journal:  Clin Oral Investig       Date:  2022-09-24       Impact factor: 3.606

3.  CYP450 polymorphisms and clinical pharmacogenetics of ibuprofen after lower third molar extraction.

Authors:  Giovana M Weckwerth; Thiago J Dionísio; Yuri M Costa; Bella L Colombini-Ishiquiriama; Gabriela M Oliveira; Elza A Torres; Leonardo R Bonjardim; Adriana M Calvo; Troy Moore; Devin M Absher; Carlos F Santos
Journal:  Eur J Clin Pharmacol       Date:  2020-11-17       Impact factor: 2.953

4.  RT-qPCR study of COX-1 and -2 genes in oral surgical model comparing single-dose preemptive ibuprofen and etoricoxib: A randomized clinical trialy.

Authors:  Assis-Filipe Medeiros-Albuquerque; Cristiane-Sá Roriz-Fonteles; José-Jackson do Nascimento-Costa; José-Roberto Viana-Silva; Paulo-Goberlânio de Barros-Silva; Eduardo-Costa Studart-Soares; Filipe-Nobre Chaves; Karuza-Maria Alves-Pereira; Thyciana-Rodrigues Ribeiro; Fábio-Wildson Gurgel-Costa
Journal:  J Clin Exp Dent       Date:  2020-04-01

5.  Targeted enhancement of the therapeutic window of L19-TNF by transient and selective inhibition of RIPK1-signaling cascade.

Authors:  Sheila Dakhel; Tiziano Ongaro; Baptiste Gouyou; Mattia Matasci; Alessandra Villa; Dario Neri; Samuele Cazzamalli
Journal:  Oncotarget       Date:  2019-11-19

6.  Preemptive Oral Etoricoxib on Health-Related Quality of Life after Mandibular Third Molar Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Long Xie; Zhi Li; Zheng-Jun Shang
Journal:  Biomed Res Int       Date:  2021-03-06       Impact factor: 3.411

Review 7.  Analgesic Efficacy of Etoricoxib following Third Molar Surgery: A Meta-analysis.

Authors:  Lorenzo Franco-de la Torre; Diana Laura Franco-González; Lorena Michele Brennan-Bourdon; Nelly Molina-Frechero; Ángel Josabad Alonso-Castro; Mario Alberto Isiordia-Espinoza
Journal:  Behav Neurol       Date:  2021-09-08       Impact factor: 3.342

8.  Effect of preemptive photobiomodulation associated with nimesulide on the postsurgical outcomes, oxidative stress, and quality of life after third molar surgery: a randomized, split-mouth, controlled clinical trial.

Authors:  Edson Luiz Cetira Filho; Paulo Goberlânio Barros Silva; Deysi Viviana Tenazoa Wong; Celia Choquenaira-Quispe; Francisco Rafael Alves Santana Cesário; Gisele de Sousa Nogueira; Alan Vieira Costa de Sousa; Andréa Silvia Walter de Aguiar; Said Goncalves da Cruz Fonseca; Fabio Wildson Gurgel Costa
Journal:  Clin Oral Investig       Date:  2022-08-11       Impact factor: 3.606

9.  Preemptive analgesia-related gene and protein expression in third molar surgeries under non steroidal anti-inflammatory drug protocols: A PROSPERO-registered systematic review of clinical studies.

Authors:  A-F Medeiros-Albuquerque; C-M Sampaio-Melo; E-C Studart-Soares; T Rodrigues-Ribeiro; C-S Roriz-Fonteles; K-M Alves-Pereira; D-A Ferreira-Barbosa; P-G de-Barros-Silva; F-W Gurgel-Costa
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2018-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.